Positioning of the project:
The research Engineer position is proposed in the frame of the H2020 European Project R-LiNK. The consortium consists of 22 European partners including research institutes, hospitals, clinical investigation center and companies.
Bipolar disorder (BD) is a prevalent mental disorder and a leading cause of suicide. Lithium is the key mood stabilizer for prevention of BD relapse and suicide. Whilst many cases become asymptomatic with lithium treatment, the majority show sub-optimal response. Identifying biomarkers for predicting lithium response would enable personalization of treatment define criteria for stratification of BD cases and further refine the clinical response phenotype.
In fact, 1/3 of patients under lithium treatment show impressive improvements of the mental health. 1/3 show no response to the treatment. For others the poor adherence to treatment may be the cause of an apparent non-response to lithium therapy.
One of the objectives of the proposal is to develop a self-monitoring medical device used to enhance adherence to treatment and monitor the Li level in saliva. The idea is that, becoming actors of their treatment, patients will increase their adherence to lithium therapy.
More info :